CXCR4: a unique chemokine receptor
Chemokines are defined by their ability to induce directional migration of cells toward a gradient of the chemokine (chemotaxis) through binding to a subset of seven-transmembrane, G-protein-coupled (chemokine) receptors. Chemokines are small (B8-14 kDa) secreted proteins that are divided into the two main chemokine subfamilies on the basis of the arrangement of two N-terminal cysteine residues. These cysteine residues either have an amino acid between, or they are adjacent, accounting for CXC or CC chemokines. 1 In a more functional sense, chemokines can also be classified as inflammatory or homeostatic chemokines that are induced during inflammation to attract inflammatory cells, 2 or constitutively secreted by stromal cells (homeostatic chemokines). Homeostatic chemokines, such as CXCL12, coordinate cell trafficking and homing, which is essential during development and for homeostasis and function of the immune system. 3, 4 Stromal cell-derived factor-1 (SDF-1), now designated CXCL12, 1 signals through the CXCR4 chemokine receptor, 5, 6 and was initially described as a pre-B-cell growth factor in 1994. 7 In 1996, the co-receptor function of CXCR4 for the entry of T-tropic (X4) human immunodeficiency virus (HIV)-1 strains into CD4-positive T cells was discovered. 5, 6, 8 Subsequently, CXCL12 and CXCR4 gene-deleted mice were described with an identical, lethal phenotype, suggesting a monogamous relationship between this chemokine and its receptor. The phenotype of these mice is characterized by deficient hematopoiesis with defects in B-cell development and myelopoiesis, and abnormal neuronal and cardiovascular development. [9] [10] [11] [12] More recently, CXCR7 has been described as an alternate receptor for CXCL12, which appears to function by sequestering CXCL12 13 and modifying CXCR4 signaling rather than displaying autonomous signaling in response to CXCL12.
14 Mesenchymal stromal cells (MSCs) are considered a major source for CXCL12 in the adult organism. CXCL12-secreting stromal cells can be found in various tissues, such as the liver, lungs, lymphatic tissues and the marrow. 15 Constitutive high-level CXCL12 secretion by reticular stromal cells in the marrow is essential for homing 16 and maintenance of hematopoietic stem cells (HSCs) in distinct vascular and endosteal niches for their development and growth. 17 Through CXCL12, these stromal cells also attract circulating hematopoietic progenitor cells 16 or leukemia cells 18 for homing to the marrow ( Figure 1 ). Actually, CXCR4 is the only functional chemokine receptor on hematopoietic progenitor cells, 19 emphasizing the predominant role of this chemokine receptor for homing and maintenance of HSC in the marrow niches. More recently, the architecture of niches for hematopoietic and other tissue stem cells (that is, germline stem cells, follicle stem cell, intestinal stem cell, central nervous system stem cell, and others) and the mechanism that govern stem cell homeostasis within these niches are emerging. 20, 21 Regulated migration and homing of stem cells to tissue niches are critical steps not only during embryonic development or tissue repair but also in cancer (stem) cell dissemination. 22 In this context, the CXCR4-CXCL12 axis functions as a migration mechanism broadly conserved across species that is essential for stem cell migration in multiple tissues in both the embryo and adult. The responsiveness to CXCL12 significantly changes during differentiation of hematopoietic cells, as demonstrated for lymphoid 23 and myeloid 24 cells. These maturation-dependent changes in CXCL12 responsiveness, which are not necessarily accompanied by changes in CXCR4 expression levels, 23 are thought to regulate trafficking and homing to distinct tissue microenvironments. For example, high CXCL12 responsiveness allows for the retention and homing of immature and mature B cells (pre-and pro-B cells, and plasma cells) to the marrow. [25] [26] [27] This maturation-dependent CXCL12 responsiveness appears to be retained in malignancies that correspond to respective maturation stages of their normal counterparts; that is, pre-and pro-B-cell acute lymphoblastic leukemia (ALL) cells and multiple myeloma cells utilize the CXCR4/CXCL12 axis for bone marrow homing. 18, 28 There is also growing evidence suggesting that leukemia progression is driven by a sub-population of cells referred to as leukemia stem cells (LSCs) that are more leukemogenic than other cells of the same clone. LSCs share phenotypic and functional characteristics with their normal counterparts, and the hierarchical organization of the neoplastic clone mimics differentiation and cell turnover as part of homeostasis or tissue repair, nurtured by infrequent stem cells. [29] [30] [31] Normal and malignant stem cells apparently have a particular requirement for distinct niches: HSCs localize to CXCL12 þ stromal cells that are in close proximity to the marrow vasculature (vascular niche) or the endosteum. 17 Interestingly, brain tumor stem cells also reside in vascular niches adjacent to blood vessels, 32 suggesting that normal stem cells, LSCs and other cancer stem cells (CSCs) have fundamentally similar requirements toward their niches. 21, 33 This concept implies that LSCs would preferentially localize through CXCR4 to vascular and endosteal niches that are normally restricted to HSC. Consequently, CXCR4 antagonists could mobilize LSCs and/or CSCs that are normally protected in tissue niches and make them accessible to conventional anticancer drugs.
Current clinical trials with AMD3100 utilized this mechanism of CXCR4-mediated homing to the marrow to mobilize HSC to the peripheral blood for HSC collection for autologous stem cell transplantation. 34 In phase II trials, mobilization with the combination of AMD3100 and granulocyte colony-stimulating factor (G-CSF) results in the collection of more progenitor cells than G-CSF alone. 35 The peptide CXCR4 antagonist TN14003 is also a potent mobilizer of HSC alone and in combination with G-CSF; and apparently TN14003 displays a pattern of hematopoietic cells and overall potency for HSC mobilization that is different from AMD3100. 36 The CXCR4-CXCL12 axis is also related to tissue hypoxia and repair of hypoxic damage. 37 The transcription factor hypoxiainducible factor-1 (HIF-1), which gets upregulated in hypoxic states, induces the local expression of CXCL12, 38 which in turn can attract circulating progenitor cells for tissue repair. This function of the CXCR4-CXCL12 axis plays a prominent role in the recruitment of marrow-derived progenitors to the heart after myocardial infarction. 39, 40 Currently, there are research efforts to utilize this mechanism by local intramyocardial delivery of a protease-resistant CXCL12 to attract progenitor cells to sites of hypoxic damage after myocardial infarction. 41 Moreover, in hypoxic tumors or in tumors that display mutations in the von Hippel-Lindau tumor suppressor protein pVHL (a negative regulator of HIF-1), HIF-1 upregulates CXCR4 expression, 42, 43 providing a survival benefit for tumor cells with high CXCR4 expression.
Blocking CXCR4 in the treatment of leukemia and other cancers CXCR4 chemokine receptors are expressed by leukemia cells from patients with acute and chronic leukemias and also various solid tumors, such as breast cancer, lung cancer, prostate cancer and others. 37, 44 In general, CXCR4 expression by the tumor cells allows for tumor cell migration, and homing of the neoplastic cells to sites where non-malignant stromal cells express CXCL12, the ligand for CXCR4. 45 This concept implies that tumor cell metastasis is not random, but guided by the expression of chemokine receptors and adhesion molecules on the neoplastic cells, and respective ligands in the target organs. 15, 46 Tumor cells apparently utilize this mechanism to access microenvironments, such as the marrow, that provide factors that favor their growth. For example, the importance of CXCR4 for breast cancer metastasis to different target organs was demonstrated in vitro and in vivo. 15 Leukemia cells from patients with chronic lymphocytic leukemia (CLL) and ALL utilize CXCR4 for homing to marrow stromal cells (MSCs) in vitro 47 and in vivo. 18 Moreover, CXCL12 has a direct growthand survival-promoting effect for various cancer cells, such as breast cancer cells 48 or CLL cells. 49 CXCL12 also promotes tumor progression by recruiting endothelial progenitor cells to tumors for tumor angiogenesis. 48 Stromal fibroblasts, also called carcinoma-associated fibroblasts or mesenchymal stromal cells (MSC), are part of the tumor microenvironment. These stromal fibroblasts constitutively secrete CXCL12, and contact between tumor cells and stromal cells is largely dependent on the CXCR4-CXCL12 axis. For example, co-culture between CLL cells 47 or lung cancer cells 50 and CXCL12-secreting stromal cells induces strong adhesion and spontaneous migration of the neoplastic cells beneath the stromal cells (pseudoemperipolesis) in a CXCR4-dependent manner. Nonspecific and specific CXCR4 antagonists, such as pertussis toxin and CXCR4 antagonists (T140 and AMD3100) can block this adhesion and migration. 51 Adhesion to stromal cells confers resistance to spontaneous and drug-induced cell death of tumor cells, and therefore is also termed cell adhesion-mediated drug resistance. 52, 53 Tumor cells that adhere to stromal cells through CXCR4 are therefore, at least partially, protected from the effects of cytotoxic chemotherapy and represent a reservoir for minimal residual disease (MRD) and relapses commonly seen in the treatment of patients with various cancers. However, the overall role of MSC in the tumor microenvironment remains controversial. Although on the one hand, MSC can provide survival, growth and drug resistance signals, 48, 54 MSC can also induce cell cycle and growth arrest in epithelial cancer [55] [56] [57] and leukemia cells. 58 On the basis of these findings, the therapeutic use of MSC to decelerate tumor growth has been proposed. 59, 60 These controversial findings regarding the capacity of MSCs to induce tumor progression (in vivo) and also to induce tumor cell growth arrest (in vitro) could, at least in part, be due to the ability of MSC to provide niches for CSCs in vivo. In these tissue niches, MSCs are thought to maintain and support a sub-population of growth-arrested tumor cells/CSCs that are resistant to cytotoxic treatments and function as a reservoir of the disease with the potential to proliferate and sustain the malignant process. 22 In summary, the rationale for targeting CXCR4 with CXCR4 antagonists in leukemia and other cancers is as follows:
1. disrupting the adhesive stromal interactions that confer survival and drug resistance signals to leukemia and other cancer cells; 2. mobilizing tumor cells from tissue sites, such as the marrow, and thereby making them better accessible to conventional therapy; 3. blocking of migration and dissemination of tumor cells in the process of tumor cell metastasis; 4. blocking of paracrine growth and survival signals through activation of the CXCR4-CXCL12 axis and 5. blocking pro-angiogenesis effects of CXCL12.
These different mechanisms through which CXCR4 antagonists may display activity in treatment of neoplastic diseases raise questions about when during the course of the disease and for how long they should be administered, and whether CXCR4 antagonists should be given alone or in combination with conventional anticancer drugs. This question will be addressed by clinical trials that are currently designed or ongoing.
CXCR4 antagonists
CXCR4 antagonists were initially developed as new drugs for the treatment of HIV-1 infection. At the time of their discovery in the early 1990s, the mechanism of anti-HIV activity of the most prominent CXCR4 antagonists, T140 and its analogs, 61, 62 
AMD3100
63,64 and ALX-4C, 65 was unknown. After the discovery of the co-receptor function of CXCR4 for T tropic HIV-1, the specific CXCR4-blocking function of the different CXCR4 antagonists was rapidly demonstrated. [66] [67] [68] With the rapid increase in our knowledge of other, non-HIV-related functions of CXCR4 over the past 11 years, other potential applications such as HSC mobilization and treatment of cancer and autoimmune disease are emerging and have gradually replaced the original intent to use CXCR4 antagonists as anti-HIV drugs.
In general, four major classes of CXCR4 antagonists and agonists can be distinguished: (a) small peptide CXCR4 antagonists, such as T140 and its analogs (TN14003 and others), (b) non-peptide CXCR4 antagonists, such as the bicyclam AMD3100, (c) antibodies to CXCR4 and (d) modified agonists and antagonists for SDF-1. Below, we will summarize the current status of preclinical and clinical development for CXCR4 antagonists.
Small peptide antagonist of CXCR4
Initially, this group of small peptide CXCR4 antagonists was discovered screening naturally occurring peptides for anti-HIV activity. In that process, self-defense peptides from horseshoe crabs, called tachyplesin (from the Japanese horseshoe crab Tachypleus tridentatus) and polyphemusin (from the American horseshoe crab Limulus polyphemus), were identified and chemically modified, leading to the synthesis of the anti-HIV peptides T22, 62 T134 and T140. 69 Initially, these compounds were thought to function by inhibiting HIV-1-T-cell fusion or the viral uncoating. 61 However, the precise mechanism of anti-HIV activity remained unclear until the discovery that T tropic HIV-1 (X4-HIV-1) utilizes CXCR4 as a co-receptor for cellular entry into CD4-positive T cells. Soon after this, it was demonstrated the T22 specifically binds to CXCR4 and blocks CXCR4 receptor regions that are critical for HIV-1 viral entry and for activation by its natural ligand, CXCL12.
68 T140 is considered the most active CXCR4 peptide antagonist among the initially synthesized peptides, but lacks serum stability due to cleavage of the C-terminal Arg. Therefore, C-terminally amidated T140 analogs were developed to overcome serum instability, 70 leading to the synthesis of TN14003 and TC14012. Further work revealed the binding regions for T140 within the extracellular domains and regions of the hydrophobic core of CXCR4, which are distinct from the binding region for AMD3100. 71 Also, in a series of experiments to elucidate the mechanism of CXCR4 signaling, it was noticed that T140 decreased autonomous CXCR4 signaling in CXCR4 wild-type or constitutively active CXCR4 mutants, characterizing T140 as an inverse CXCR4 agonist, whereas AMD3100 and ALX40-4C displayed partial agonist activity in this study. 72 Clinical trials will help to determine whether this characteristic of CXCR4 peptide antagonists correlates with a profile of activities and/or side effects that is distinct from AMD3100.
The efficacy of T140 and its analogs for blocking CXCR4 in vitro and in vivo has been documented in numerous preclinical studies, including in vivo models for breast cancer and melanoma, 73, 74 rheumatoid arthritis 75 and stem cell mobilization. 36 Other studies explored the activity of these agents in acute 76, 77 and chronic leukemias, 54 multiple myeloma, 78 small cell lung cancer (SCLC), 50 malignant melanoma 74 and pancreatic cancer. 79 Besides these disease-oriented studies, T140 and its analogs have been used in basic studies exploring the function of CXCR4 in dendritic cell development 80 and migration, 81 B-cell homing and germinal center positioning within lymphatic tissues, 82 and HSC homing. 83 Currently, the T140 analog TN14003 is under clinical development by Biokine Therapeutics Ltd, Rehovot, Israel.
ALX40-4C is a polypeptide of nine Arg residues that is stabilized by terminal protection and inclusion of D-amino acids. ALX40-4C is a specific CXCR4 antagonist, 66 and was the first CXCR4 antagonist clinically used in phase I and phase I/II trials in HIV patients conducted by the Canadian company Allelix Biopharmaceuticals, Mississauga, ON, Canada. 65 This peptide is no longer under development, particularly because of formulation difficulties and lack of efficacy, and also because it is unlikely that an oral formulation of this complex peptide can be produced.
Non-peptide CXCR4 antagonists
AMD3100 is a bicyclam, in which two cyclam rings are connected through an aromatic bridge. AMD3100 possesses the highest anti-HIV activity among a series of bicyclams that were synthesized in the early 1990s. 64, 84 AMD3100 is a specific antagonist of CXCL12 binding to CXCR4, inhibiting CXCL12-mediated calcium mobilization, chemotaxis and GTP binding, and does not cross-react with other chemokine receptors.
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AMD3100 was initially considered to interfere with HIV-1 fusion or uncoating. 63 Initially developed at Johnson Matthey in collaboration with the Rega Institute for Medical Research (Leuven University, Leuven, Belgium), this compound was first called JM3100, which changed to AMD3100 after a new company (AnorMED, Langley, BC, Canada) took over the development. The anti-HIV-1 activity of AMD3100, restricted to X4-HIV-1 strains, and the blocking function of AMD3100 on gp120 interaction with CXCR4 during viral entry 86 were the initial focus during the early development of this drug. However, an unexpected rapid, transient leukocytosis was noticed during phase I/II clinical trials of AMD3100 in volunteers and HIV-infected patients, caused by the mobilization of various hematopoietic cells, including CD34-positive HSC, to the blood. 87, 88 In the second trial in HIV patients, one patient receiving the highest dose of AMD3100 (160 mg/kg/h) had a significant drop in his viral load, but overall the efficacy of AMD3100 in affecting disease activity in HIV-1 patients was considered low and therefore this application was not further pursued for AMD3100. Instead, AnorMED explored AMD3100 as a mobilizing agent for HSC, 88 and a subsequent series of preclinical and clinical trials demonstrated that AMD3100 alone and in combination with G-CSF mobilizes HSC. 34, 89, 90 AMD3100 (recently re-named as Plerixafor or Mozobil) is now owned by Genzyme Corporation (Cambridge, MA, USA) after a recent takeover of AnorMED by Genzyme in late 2006. Plerixafor is currently used in phase III trials in lymphoma and multiple myeloma patients undergoing autologous stem cell mobilization, and current plans are to file for US and European approval of the drug in 2008. The activity of Plerixafor to inhibit CXCR4 activation in various in vitro and in vivo tumor models, such as inhibition of CXCL12-induced tumor cell migration and downstream signaling and activity in murine tumor models has been reported. These studies are summarized in Table 1. AMD070 is another orally bioavailable small molecule CXCR4 antagonist with anti-HIV activity that Genzyme is currently developing in phase II trials for HIV-1 treatment. 91 KRH-1636 is an orally available, non-peptide CXCR4 antagonist that inhibits infection by X4-HIV-1 virus and blocks responses to stimulation with CXCL12, such as calcium mobilization. 92 
Development antibodies to CXCR4
Neutralizing the interaction between CXCL12, the ligand for CXCR4, and CXCR4 by using anti-CXCR4 antibodies significantly inhibit HIV infection and tumor cell migration in vitro. 47, 93, 94 Furthermore, anti-human CXCR4 or CXCL12 antibodies also significantly impair metastasis and progression of non-Hodgkin's lymphoma, breast, lung and prostate tumors in animal models. [95] [96] [97] [98] The unique properties of monoclonal antibody (mAb) therapies, including their high affinity and specificity, and the differential expression of target antigen in tumor cells versus normal cells make them attractive agents for cancer immunotherapy. Development of therapeutic mAbs to CXCR4 is challenging due to the fact that CXCR4 can exhibit conformational heterogeneity. Using a panel of mAbs to CXCR4, it was found that CXCR4 on both primary and transformed T, B and myeloid cells exhibited considerable conformational heterogeneity. 99 This conformational heterogeneity of CXCR4 explains the cell-type-dependent ability of CXCR4 antibodies to block chemotaxis to its ligand CXCL12. In addition, the mAb most commonly used to study CXCR4 expression, 12G5, recognizes only a sub-population of CXCR4 molecules on all primary cell types analyzed. As a result, CXCR4 concentrations on these important cell types have been underestimated to date. The factors responsible for altering CXCR4 conformation are not known. However, CXCR4 can be posttranslationally modified by sulfation of its N-terminal tyrosines, and by a chondroitinsulfate chain at serine 18. This phenmenon may explain, in part, the difference in confirmation, antibody specificity and function of CXCR4. 100 Altered glycosylation patterns, neoexpression and underexpression or overexpression of glycans are hallmarks of cancer and may significantly affect the activity of various CXCR4 antagonists in development.
Modified CXCL12
CTCE-9908 and CTCE-0214 are peptide analogs of CXCL12 with inhibitory and agonist activity, respectively. CTCE-9908 that has received orphan drug status by the Food and Drug Administration for the treatment of osteogenic sarcoma. CTCE-9908 decreases growth and adhesion of osteosarcoma cells and the metastatic dissemination of cancer cells in two murine models. 101 CTCE-9908 is developed by Chemokine Therapeutics Corp., Vancouver, BC, Canada.
CXCR4 antagonists in selected cancers
CLL B-cell CLL is a leukemia of mature, antigen-experienced B cells. CLL cells accumulate in the blood, marrow and secondary lymphoid tissues. Despite their apparent longevity in vivo, isolated CLL cells generally undergo spontaneous apoptosis in vitro when cultured under conditions that support the growth of human B-cell lines. 49 CLL cells express high levels of CXCR4, 47, 102 and CLL cells spontaneously migrate beneath MSCs that secrete CXCL12 in a CXCR4-dependent manner. 47 Stromal cells and nurse-like cells, another stromal cell type derived from monocytes, protect CLL cells from spontaneous or drug-induced apoptosis in a contactdependent manner. These observations support a model proposing that expression of CXCR4 by CLL cells allows for their recirculation between the blood and the marrow or lymphoid tissues, where they receive protective survival signals. We demonstrated earlier that CXCR4 antagonists effectively block CXCL12-induced activation, migration and signaling of CLL cells. 54 Also, CXCR4 antagonists reversed stromal cell-mediated protection from spontaneous or fludarabine-induced apoptosis of CLL cells, suggesting a potential role of CXCR4 antagonists in combination with a B-celltargeted therapy in the treatment of CLL. Because of the high-level CXCR4 expression, and the particular requirement of stromal cell support for CLL cell survival, it appears that CLL patients would particularly respond to CXCR4 antagonists. The expected response to CXCR4 antagonists would be a mobilization of the CLL cells from the tissues (marrow and lymphoid tissues) to the blood, where CLL cells then could be targeted by mAbs, such as anti-CD20 or anti-CD52 mAbs, or cytotoxic agents.
Acute myeloid leukemia
Despite a general sensitivity to chemotherapy, long-term disease-free survival in patients with acute myelogenous leukemia (AML) is low because a majority of patients relapse from MRD. The marrow is considered the primary site for MRD where adhesion to stromal elements may protect AML cells from cytotoxic drugs. Several studies indicated that adhesion to MSCs affects the survival and proliferation of AML cells 58, 103, 104 and protects AML cells from chemotherapy in vitro 105 and in vivo. 106 Adhesion molecules, in particular the very late antigen-4 (VLA-4) integrins, along with CXCR4 chemokine receptors, are essential for AML cell adhesion to respective ligands (fibronectin and VCAM-1) on stromal cells 107 and for protection of AML cells from spontaneous or drug-induced apoptosis. 106, 108 CXCR4 receptors are functional in AML, 58, 109 and surface CXCR4 expression, which is generally low when compared with lymphoid cells, correlates with functional responses, such as chemotaxis. 110 CXCR4-dependent engraftment of AML cells in non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice was demonstrated by Tavor et al., 111 and this group also reported that the proteolytic enzyme elastase is involved in regulating SDF-1-dependent migration and proliferation of AML cells in vitro and in vivo.
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CXCR4, in cooperation with VLA-4 integrins, mediates spontaneous migration of AML cells beneath MSCs, along with a decreased proliferation of migrated AML cells within stromal layers. 58 This suggests that CXCR4 expression by AML cells 128 Small cell lung cancer (SCLC) T140 and its analogs block adhesion and survival pathways 50, 130 Pancreatic cancer AMD3100 inhibits tumor cell migration and growth 134 Cholangiocarcinoma AMD3100 inhibits tumor cell migration 135 Gastric cancer AMD3100 reduced tumor growth in a murine model 136 Colorectal cancer AMD3100 inhibits tumor cell growth 137 Malignant melanoma AMD3100 inhibits tumor cell activation and proliferation favors the enrichment of a non-cycling sub-population of AML cells within the stromal layer. These cells may be less susceptible to cytotoxic treatments, and they may represent dormant leukemia progenitors serving as a reservoir for MRD. 113 This function of CXCR4 could explain why CXCR4 surface expression on AML cells has such a profound negative prognostic impact in AML. [114] [115] [116] Plerixafor is currently used in an ongoing clinical trial for mobilization of AML cells from the protective marrow microenvironment to the blood, where the AML cells are then targeted by conventional cytotoxic drugs. The feasibility of using Plerixafor for AML cell mobilization to the blood in an animal model and in AML patients on this trial was recently reported. 117, 118 CXCR4 in ALL Precursor B-cell ALL, the most common childhood malignancy and the second most common adult acute leukemia, is characterized by a high motility of the leukemia cells, resulting in leukemic infiltrates into extramedullary sites. In particular, ALL cells have a high affinity for the central nervous system, which is the most common location for extramedullary relapses, but also for the liver, spleen and the lymph nodes. The presumed normal counterparts of B-ALL cells are precursor B cells that are highly dependent on the stromal microenvironment during their maturation in the marrow. 119 Contact between precursor B cell and CXCL12-secreting stromal cells is maintained by CXCR4 expression on the B cells, and gene deletion of CXCR4 or CXCL12 in mouse models results in premature release of B-cell precursors into the circulation. 25 We reported that B-ALL cells express functional CXCR4 receptors that induce leukemia cell chemotaxis to CXCL12 and spontaneous migration beneath CXCL12-secreting stromal cells in a CXCR4-and VLA4 integrin-dependent manner, using the B-cell precursor lines NALM-6 and REH, 47, 120 findings that were subsequently confirmed with primary ALL cells. 121, 122 CXCR4 receptors on ALL cells participate in homing of leukemia cells to the marrow in NOD/SCID mice. 123, 124 A recent study by Sipkins et al. 18 provided in vivo evidence that CXCR4 is necessary for homing of ALL cells to the marrow. Blocking CXCR4 on ALL cells with specific CXCR4 receptor antagonists blocked the migration of ALL cells to CXCL12 and MSCs, and partially disrupted the protection of ALL cells from cytotoxic agents by MSCs. 76 One of the mechanisms by which MSCs protect ALL cells from chemotherapeutic agents is related to asparagine synthetase, an enzyme that is critical to the biosynthesis of asparagine. MSCs constitutively secrete asparagine synthetase, 125 which interferes with asparaginase, a drug that has a critical impact in the treatment of ALL patients. Through this mechanism, ALL cells may survive in marrow stromal niches and thus represent the seed for residual disease and relapses. 126 Collectively, these studies suggest that ALL cells should be particularly responsive to therapeutic attempts for mobilization with CXCR4 antagonists. ALL cells mobilized in such a way from marrow or other tissue niches then could be better targeted by conventional ALL treatments.
CXCR4 in breast cancer
CXCR4 was the first chemokine receptor that was described to be functionally expressed by breast cancer cells. 15 Initially, the main function of CXCR4 in breast cancer was considered to be the directed, organ-specific metastasis of circulating CXCR4-positive cancer cells to CXCL12-expressing target organs, such as the lungs, liver, lymphatic tissues and the marrow. 15 Treatment with anti-CXCR4 antibodies reduced local and systemic metastasis of breast cancer in an animal model. 15 Subsequently, additional functions of the CXCR4-CXCL12 axis in breast cancer have been described: first, CXCR4 activation on breast cancer cells induces a growth response in the tumor cells (paracrine function of CXCL12), and second, CXCL12 recruits endothelial progenitor cells to the tumor for tumor angiogenesis (endocrine function of CXCL12). 48 Stromal fibroblasts, also termed carcinoma-associated fibroblasts, constitutively secrete CXCL12 into the tumor microenvironment. 45, 48 High-level expression of CXCR4 on neoplastic cells is associated with relatively poor overall survival in patients with breast cancer. 127 The multiple tumor-promoting effects of CXCL12 in breast cancer suggest that CXCR4 antagonists alone or in combination with cytotoxic drugs could decrease the rate of recurrence in the adjuvant setting where patients are likely to have MRD, and/or increase the response rates to conventional therapy in advanced stages of the disease. Animal breast cancer models using T140 73 and Plerixafor 128 have shown promising results, suggesting that CXCR4 antagonists should be explored in this cancer.
CXCR4 in lung cancer
SCLC is an aggressive, rapidly metastasizing cancer. Even with combination chemotherapy and radiotherapy treatments, the 5-year survival is only 5% due to rapid development of drug resistance. CXCR4 is the major chemokine receptor expressed by primary SCLC cells or SCLC cell lines. 50, 129 CXCR4 activation induces migratory and invasive responses in SCLC cells, and adhesion to CXCL12-secreting stromal cells in a CXCR4-and integrin-dependent manner. 50 Moreover, signaling through CXCR4 on SCLC cells induces activation and signaling of integrin adhesion molecules expressed on the SCLC cells. 130 Integrin-mediated adhesion of SCLC cells to stroma and extracellular matrix in turn protects SCLC cells from chemotherapyinduced apoptosis. 130, 131 Collectively, CXCR4 cooperates with integrins in SCLC cells, mediating tumor cell adhesion to stromal cells, which in turn confers drug resistance and tumor cell growth. Moreover, CXCR4 may direct the distinct metastatic pattern observed in patients with SCLC with a high propensity for bone marrow involvement. The neoplastic cells in NSCLC also express CXCR4, but at levels that are lower than in SCLC. 50 Because of the very transient responses to cytotoxic chemotherapy in lung cancer patients, particularly in SCLC, mobilization of tumor cells from their protective microenvironment using CXCR4 antagonists could be an attractive new approach and combination partner for conventional chemotherapy of lung cancer patients.
Potential side effects of CXCR4 antagonists
Permanent or long-term inhibition of the CXCR4-CXCL12 axis would potentially expose patients to risks of immune system and hematopoietic dysfunctions. T and B lymphocytes utilize CXCR4 for trafficking and homing to distinct microenvironments within lymphoid tissues and the thymus during development and immune surveillance. 82, 132 Another general concern regarding the use of CXCR4 antagonists in cancer patients is the mobilization of normal progenitor cells, such as HSC from their microenvironments to the blood. Mobilized HSCs that are normally protected in marrow niches would be exposed to the effects of cytotoxic drugs in trials where CXCR4 antagonists are administered along with cytotoxic drugs, which could result in prolonged cytopenias. More specific side effects are Plerixafor-related cardiac complications (premature ventricular contractions) in two patients treated with 40 and 160 mg/kg/h, who had a history of cardiac problems. 88 No cardiac side effects were reported for the subsequent clinical trials of Plerixafor for stem cell mobilization.
Collectively, CXCR4 antagonists provide a new, targeted tool to mobilize leukemia cells from their protective marrow microenvironment. Mobilized leukemia cells then become more accessible to conventional drugs, and therefore this strategy may help to overcome MRD and relapses commonly seen in the treatment of leukemia patients. Currently, CXCR4 antagonists are explored in proof-of-principle studies in leukemia patients in whom leukemia cell mobilization can be easily assessed and monitored. However, given the expression of functional CXCR4 receptors by a variety of other hematopoietic and epithelial cancers, 37 a broader use of CXCR4 antagonists in other cancers is expected provided that the ongoing studies are successful ( Table 2 ).
